Physician profile
John Studdard
NPI 1225022213
$3,018.14
in general payments reported to CMS, 2019-2025
18 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $768 · 2021: $660 · 2022: $53.82 · 2023: $99.76 · 2024: $58.35 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,338.24 | 2019-2025 | Nucala, Trelegy Ellipta |
| Philips North America LLC | $295.32 | 2019-2021 | |
| Genentech USA, INC. | $262.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.34 | 2019-2020 | |
| Insmed, INC. | $169.72 | 2019-2020 | |
| Inari Medical, INC. | $129.68 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $102.60 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $91.91 | 2019-2020 | |
| Grifols USA, LLC | $79.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $64.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.24 | 2019 | |
| Gilead Sciences, INC. | $49.22 | 2019 | |
| Abbvie INC. | $39.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.21 | 2019-2020 | |
| Pfizer INC. | $22.77 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.45 | 2025 | |
| Boston Scientific Corporation | $16.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Studdard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.